CHI3L1 and myeloid sarcoma: Subsequently, candidate biomarkers in CSF and serum of MS were validated by enzyme linked immunosorbent assay (ELISA), confirming that CSF and serum’s CHI3L1 CHI3L2 levels were associated with the disease stage (Hinsinger et al., 2015).